| 1 |
33200682 | Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules. | 2022 May |
1 |
| 2 |
35149545 | MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. | 2022 May 4 |
1 |
| 3 |
35227966 | Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. | 2022 Apr |
4 |
| 4 |
35373356 | Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition. | 2022 Apr 4 |
2 |
| 5 |
32996364 | Lorlatinib induced proteinuria: A case report. | 2021 Jun |
3 |
| 6 |
33147606 | Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. | 2021 Jan 1 |
2 |
| 7 |
33449423 | Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants. | 2021 Feb |
3 |
| 8 |
33558279 | Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma. | 2021 Feb |
1 |
| 9 |
33613692 | Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. | 2021 |
2 |
| 10 |
33685866 | Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. | 2021 May 15 |
7 |
| 11 |
33814929 | Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib. | 2021 |
3 |
| 12 |
33917039 | Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics. | 2021 Apr 7 |
2 |
| 13 |
33973232 | Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer. | 2021 Nov |
2 |
| 14 |
34080140 | The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden. | 2021 Aug |
1 |
| 15 |
34080177 | Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. | 2021 Aug |
1 |
| 16 |
34125313 | ROS1 Targeted Therapies: Current Status. | 2021 Jun 14 |
1 |
| 17 |
34157012 | Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors. | 2021 Jul 1 |
3 |
| 18 |
34210658 | Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma. | 2021 Aug |
2 |
| 19 |
34320493 | Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report. | 2021 |
2 |
| 20 |
31705129 | Lorlatinib in ROS1-positive NSCLC. | 2020 Jan |
1 |
| 21 |
31977471 | 18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer. | 2020 Mar |
2 |
| 22 |
32060867 | Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. | 2020 Feb |
1 |
| 23 |
32208297 | A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. | 2020 May |
11 |
| 24 |
32344248 | Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. | 2020 Jun |
1 |
| 25 |
32360579 | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. | 2020 Sep |
3 |
| 26 |
32409267 | Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. | 2020 Sep |
2 |
| 27 |
32416346 | A user's guide to lorlatinib. | 2020 Jul |
1 |
| 28 |
32511029 | Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer. | 2020 Sep |
1 |
| 29 |
32681682 | Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. | 2020 Oct |
2 |
| 30 |
32718541 | Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC. | 2020 Aug |
1 |
| 31 |
32776005 | Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? | 2020 Jun |
2 |
| 32 |
32799090 | GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. | 2020 Oct |
3 |
| 33 |
32871626 | Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. | 2020 Nov |
1 |
| 34 |
33116594 | Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors. | 2020 |
1 |
| 35 |
33171712 | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. | 2020 Nov 7 |
4 |
| 36 |
30604291 | Lorlatinib: First Global Approval. | 2019 Jan |
2 |
| 37 |
30657349 | Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. | 2019 Mar |
2 |
| 38 |
30683630 | Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. | 2019 May |
3 |
| 39 |
30816885 | Lorlatinib for the treatment of patients with non-small cell lung cancer. | 2019 Feb |
2 |
| 40 |
30890623 | Clinical Management of Adverse Events Associated with Lorlatinib. | 2019 Aug |
2 |
| 41 |
30892989 | ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. | 2019 Jun 1 |
1 |
| 42 |
31669155 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. | 2019 Dec |
4 |
| 43 |
32914039 | Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation. | 2019 |
1 |
| 44 |
28893136 | Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations. | 2018 Sep |
7 |
| 45 |
29782561 | Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start. | 2018 Apr |
1 |
| 46 |
30171048 | Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. | 2018 Dec 15 |
2 |
| 47 |
30258534 | Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib. | 2018 Sep 13 |
2 |
| 48 |
30413378 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. | 2018 Dec |
1 |
| 49 |
28318251 | Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK. | 2017 Apr 24 |
1 |
| 50 |
28431340 | First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. | 2017 Jul 7 |
2 |